Best MariTide Alternatives in 2026: What You Can Actually Get Right Now

The RX Index is independent guidance for choosing your GLP-1 path. We score providers and treatment routes on what actually matters — clinical legitimacy, care quality, transparency, access, and cost — then help you decide where to start.

How we make money: some links here are affiliate links, and we may earn a commission if you use them. Our rankings come from the visible criteria below — legal access, clinical evidence, how MariTide-like the option is, dosing, price transparency, and care route — not commission. This page is education, not medical advice; GLP-1 medications need a licensed clinician’s OK.

Here’s the short version, because you’ve probably already scrolled past five pages that buried it.

The best MariTide alternatives in 2026 are drugs you can actually get today — and two approved weekly shots already match the roughly 20% weight loss that made MariTide a headline. MariTide (also called maridebart cafraglutide, or AMG 133) is Amgen’s once-a-month shot, and it’s still stuck in clinical trials. You can’t buy it. Not from a pharmacy, not from a telehealth site, and definitely not from a “research peptide” seller.

So the real question isn’t how do I get MariTide. It’s what’s the closest thing I can start now? And that comes down to one thing: what made you want MariTide in the first place. Give us two minutes and you’ll know exactly which option fits you — and what it costs.

Best MariTide alternatives at a glance

We back up every line above with sources, real prices, and an honest scoring system below. First, the question almost everyone gets wrong.

Can you actually get MariTide right now?

No. MariTide is still investigational, which means it’s being tested but is not yet approved or for sale. Amgen is studying it in a large set of Phase 3 trials called the MARITIME program, and describes it as an investigational once-monthly injection. You can’t get it from a normal pharmacy, a telehealth provider can’t prescribe it, and no compounding pharmacy can legally make a copy of it.

That one fact reshapes everything. Let’s break it down.

What “investigational” really means for you

A drug goes through phases of testing before the FDA decides whether to approve it. MariTide is in Phase 3 — the last big stage — in trials like MARITIME-1 (obesity) and MARITIME-2 (obesity plus type 2 diabetes). Amgen has not announced a launch date. A normal launch would still require finished Phase 3 results, a submission to the FDA, FDA review and approval, manufacturing, and then store shelves. Industry analysts expect that to land in the late 2020s at the earliest.

How good was MariTide in trials?

In its Phase 2 study (published in the New England Journal of Medicine in late 2025), people lost up to about 20% of their body weight at 52 weeks, and the weight loss hadn’t flattened out yet at the one-year mark. (Source: Jastreboff et al., NEJM, 2025.) Those are strong, exciting numbers.

But here’s the part the hype skips: those are investigational results, not proven, approved performance. And two shots you can already get hit that same ~20% range.

One honest note: trial averages are not a promise of what you’ll lose. Your results depend on your starting point, your dose, whether you tolerate the drug, your diet and activity, and whether you can stay on it.

What if you want MariTide and nothing else?

That’s fair. If the monthly shot is the whole point for you, the only legitimate path is a clinical trial. You can look into active MARITIME studies and ask who qualifies, where they’re located, and whether you might get a placebo. We list current trial status further down.

What are the best MariTide alternatives you can get right now?

The closest available match is Zepbound (tirzepatide). It’s FDA-approved, you can get it today, and it produced 20.2% average weight loss at 72 weeks in a head-to-head trial against Wegovy. Like MariTide, it works on two gut-hormone pathways at once. The big difference: it’s a weekly shot, not monthly, because no approved monthly GLP-1 exists yet.

GLP-1 and GIP are two natural gut hormones that help control hunger and blood sugar. MariTide blocks the GIP pathway while switching on GLP-1. Tirzepatide does the opposite on GIP — it switches it on too. Different routes, similar destination: strong appetite control and weight loss.

How we score MariTide alternatives

This is our own framework — an editorial tool, not a medical ruling. We weight the things that matter when you’re trying to replace a drug you can’t get:

What this score is NOT: it’s not proof one drug is medically better for you, it’s not a head-to-head clinical ranking, and it does not treat investigational results as equal to approved ones. Your clinician’s call always wins over our table.

MariTide Alternative Match Score

*Weight-loss figures come from different trials with different people, so they aren’t directly comparable. The “with full adherence” numbers assume everyone stayed on treatment; measured across everyone regardless of adherence, Wegovy HD was 18.8% and the Wegovy pill 13.6%. Zepbound’s 20.2% is from a head-to-head trial measured the same “regardless of adherence” way — which is why it edges the others on the apples-to-apples comparison. (Sources: SURMOUNT-5, STEP UP, OASIS 4, ATTAIN-1.)*

One honest thing before you click

We point most readers to Ro (sponsored affiliate link, opens in a new tab) for the approved options, so we owe you the trade-off. Ro is NOT the cheapest way to get these drugs, it does NOT offer a monthly shot, and its weight-loss program is built around FDA-approved medication — not compounded versions. If a rock-bottom sticker price is your only goal, a cash-pay compounded program will quote you less (we cover that route below, fairly).

But here’s why that flaw flips into a benefit for most people: because Ro works with FDA-approved medication and runs an insurance concierge (a team that handles the insurance paperwork for you), a member whose plan covers the drug can pay as little as a $25–$50 copay — for a medication that’s actually been through full FDA review. That certainty is usually the exact reason people got excited about an Amgen-backed drug like MariTide in the first place.

Want the bigger picture first? See our full ranking of the best GLP-1 online programs.

MariTide vs Zepbound vs Wegovy: which is closest?

Zepbound is the closest practical high-efficacy option — it’s FDA-approved, available now, and works on both the GLP-1 and GIP pathways, like MariTide. Wegovy HD is the closest match inside the semaglutide family, while the Wegovy pill and Foundayo are the better fit if avoiding injections matters more to you than matching MariTide’s monthly-shot idea.

Here’s the honest read on the numbers. In the one trial that tested them head-to-head, tirzepatide beat semaglutide 20.2% to 13.7% at 72 weeks. Wegovy HD’s headline 20.7% comes from a different trial against placebo, and that’s the “if you stay perfectly on it” figure; measured across everyone, it was 18.8% — just under Zepbound’s head-to-head 20.2%. So all three are excellent, but on a fair comparison, Zepbound has the edge.

One more thing: your body is not a trial average. Some people respond better to semaglutide than tirzepatide, and side effects differ from person to person. The “best” drug is the one you tolerate and can stay on.

Going deeper on these two? See Zepbound vs Wegovy.

Is there a monthly GLP-1 alternative to MariTide?

No. As of June 16, 2026, there is no FDA-approved once-monthly GLP-1 for weight loss. Approved options include weekly injections (Zepbound, Wegovy, Wegovy HD), daily oral tablets (Foundayo, the Wegovy pill), and older daily injections such as Saxenda. MariTide’s once-monthly schedule is the one thing you genuinely can’t match yet — and any site claiming otherwise is selling you something.

We say this plainly because it’s the part other pages dodge. If “fewer shots” was your real reason for wanting MariTide, you have two honest choices: take a daily pill now (no needles at all), or wait and watch the trials.

The needle-free pills:

• Foundayo (orforglipron): the newest option, approved April 2026. A once-daily pill with no food or water restrictions, which makes it the easiest to fit into a normal day. Weight loss was about 12.4% at 72 weeks — real, but less than the top shots.
• Wegovy pill (oral semaglutide 25 mg): approved December 2025. A once-daily pill in the well-known semaglutide family, with about 16.6% weight loss when taken consistently.

A pill solves “I hate needles” better than it solves “I want monthly.” If skipping injections is the priority, this is your lane.

Which MariTide alternative is right for you?

The right pick depends on the one thing that drew you to MariTide. If it was the dramatic weight loss, go for the strongest approved shot. If it was cost, read the compounded section below before deciding. If you have insurance, the path is different again. Find yourself here.

If you wanted the strongest weight loss

Two approved shots already hit MariTide’s range — you don’t have to wait. Zepbound (tirzepatide) is our top match: 20.2% average weight loss in a head-to-head trial, available now, and it works on both hormone pathways. Wegovy HD (semaglutide 7.2 mg) is the semaglutide-family option at 20.7% with full adherence — but it’s a step-up dose, so you can’t start on it. You begin on the 2.4 mg dose, stay there at least 4 weeks, then move up if you need more.

If big weight loss is what you came for, you can start that path today.

If you want the lowest possible cost

This is where many people land, and it needs the most care — so read the compounded section just below before you decide. Short version: cheaper options exist, but in 2026 they aren’t a like-for-like swap for an approved drug, and the rules are tightening fast.

If you have insurance (or want to use it)

This is where Ro pulls ahead. Ro doesn’t bill insurance for its membership, but its insurance concierge handles the prior authorization (the approval form insurers require) for your medication. If your plan covers Wegovy or Zepbound, that can bring your cost down to a $25–$50 copay. Most cash-pay programs leave you to fight that battle alone.

How much do MariTide alternatives cost in 2026?

MariTide has no normal price because it isn’t approved. The approved alternatives run from about $149 a month (some pills) to $449 a month (higher-dose shots) if you pay cash — and as low as $25 a month with commercial insurance and a savings card. Here’s the current breakdown, checked against the makers’ own sites on June 16, 2026.

Prices change often. We re-verify them monthly and update the “Last verified” date. Cash prices above are what the manufacturers and Ro publicly state; your final cost depends on your dose, coverage, and pharmacy. (Sources: LillyDirect, NovoCare, Ro.)

What about insurance and Medicare?

Coverage exists, but it almost always needs prior authorization, and not every plan covers weight-loss drugs. With commercial insurance plus a manufacturer savings card, Zepbound, Wegovy, and Foundayo can drop to about $25 a month.

For Medicare, a new pilot called the Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027. Eligible Medicare Part D members can get Foundayo, Wegovy (injection and tablets), and the Zepbound KwikPen for a flat $50 a month when the drug is prescribed for weight management and CMS’s clinical criteria are met. Note the fine print: the Zepbound single-dose vial and single-dose pen are not included, and Mounjaro, Ozempic, and compounded GLP-1s aren’t covered through the Bridge. (Source: CMS.)

Trying to use Medicare? See our Medicare GLP-1 Bridge application guide.

Is compounded semaglutide or tirzepatide a real MariTide alternative?

Compounded versions are cheaper and still available through some telehealth sites, but in 2026 they are not a like-for-like swap for an approved drug — and they are definitely not MariTide. Compounding means a licensed pharmacy mixes a custom version of a medication. During the recent shortages, certain compounders relied on shortage-related pathways to make semaglutide or tirzepatide. That window is closing.

Here’s the honest 2026 timeline:

• The FDA removed tirzepatide from its shortage list in October 2024 and confirmed the shortage resolved that December. It declared the semaglutide injection shortage resolved in February 2025.
• Once a shortage ends, pharmacies generally can’t keep making copies of an approved drug — the “essentially a copy” rule — unless a specific patient has a documented need for something different.
• On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list that let large outsourcing pharmacies (called 503B facilities) mass-produce them — and sent warning letters to more than 30 telehealth companies over how they marketed compounded GLP-1s. A public comment period runs through June 29, 2026.

Compounded vs FDA-approved vs the MariTide trial route

When a compounded route might make sense

Only if all of these are true for you: you want the lowest cash price, you’re working with a real licensed provider, you understand it’s not FDA-approved as a finished product, and you’re okay with a category that’s under active review. Some readers in this spot compare cash-pay compounded programs like Embody (sponsored affiliate link, opens in a new tab), which markets cash-pay compounded semaglutide and tirzepatide with fast online onboarding, direct-to-door shipping, and 24/7 provider support if treatment is appropriate. If you go this way, verify the current price, the states it serves, the pharmacy it uses, and the cancellation terms before you enroll.

When it’s the wrong route

Skip compounding if you want FDA-approved medication, you want to use insurance, you want MariTide specifically, or a seller makes claims that sound too good — like promising it’s “the same as” Wegovy or Zepbound. We never say compounded products are equivalent to, or contain the same approved drug as, the brand versions. The FDA hasn’t reviewed them the same way, and their results haven’t been proven to the same standard.

More detail: how the 2026 compounded GLP-1 rules work.

“MariTide for sale” online? Read this before you buy anything

Do not treat online listings for “MariTide,” “AMG 133,” or “maridebart cafraglutide” as a shortcut. MariTide is an investigational Amgen drug. No legitimate seller has it. The FDA has warned that unapproved GLP-1 products sold online may be harmful because their quality is unknown.

MariTide seller red-flag checklist

Watch for these:

• The words “research use only” or “not for human consumption.”
• No licensed prescriber and no prescription required.
• No named pharmacy or pharmacy paperwork.
• A claim to sell MariTide before the FDA has approved it.
• Any hint that a compounded product is “the same as” Amgen’s investigational drug.
• Prices that look too good, paid only by crypto or wire.

How to read your results: 0–2 red flags, verify much deeper before doing anything. 3 or more, walk away. And “research use only” plus no prescriber means walk away no matter what else looks fine.

The risk isn’t just wasted money. The FDA has received reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide — and it warns that unapproved products sold online may be harmful because there’s no way to know what’s really in them. There is no version of “MariTide from a website” that is safe right now.

Should you wait for MariTide, or start an approved option now?

Waiting can make sense if you specifically want MariTide and qualify for a trial — but it’s not automatically the smarter health choice. If you have a real reason to treat your weight now, the practical next step is a conversation with a licensed clinician about approved options, not waiting on an investigational drug with no announced launch date.

If your goal is “monthly MariTide, specifically” → look into a clinical trial.

If your goal is “start an effective, legal GLP-1 now” → compare Zepbound, Wegovy HD, Foundayo, and the Wegovy pill.

It’s fine to wait if: you only want MariTide, you’re trial-eligible and comfortable with the rules, you’re healthy and not in a hurry, and you accept approval isn’t a sure thing. It makes more sense to start now if: you want a legal prescription today, you have weight-related health risks, you want insurance help, or you want a drug with known labeling and provider follow-up.

MARITIME trial status

Last checked: June 16, 2026

Trial status changes often. Check the current study record at ClinicalTrials.gov before making plans. (Source: ClinicalTrials.gov, June 16, 2026.)

Already on Wegovy or Zepbound? What to ask before you switch

Don’t switch GLP-1s because of a headline about a newer drug. A new option being exciting doesn’t make it better for you. Before changing anything, run through this with your prescriber.

• What am I on now, and what dose?
• Am I losing weight, stalled, or dealing with side effects?
• Do I have diabetes or other conditions that change the math?
• Does my insurance cover what I’m taking now?
• Would switching make me restart the slow dose ramp-up?
• What happens if the new drug isn’t covered?

Hold off on switching on your own if you’re having serious side effects, you take several medications, you’re pregnant or planning to be, or you’re already doing well. “Doing well” is a good reason to stay put.

Who should not use this page to choose a GLP-1?

Use this page to compare routes, not to decide medical eligibility. GLP-1 medications aren’t right for everyone, and some people need a clinician’s sign-off before going anywhere near them. Talk to a clinician first if you’re pregnant or planning pregnancy, have a personal or family history of medullary thyroid cancer or the condition MEN2, have had pancreatitis, have gallbladder disease or severe stomach problems, have kidney issues or get dehydrated easily, or take insulin or a sulfonylurea (a common diabetes pill).

These cautions appear across GLP-1 labels, including Foundayo’s, which carries warnings about thyroid tumors, pancreatitis, gallbladder problems, kidney injury, severe stomach issues, low blood sugar when combined with certain diabetes drugs, and pregnancy. None of that means a GLP-1 is wrong for you — it means the decision belongs with a clinician who knows your history.

What we actually verified for this page

We don’t expect you to take our word for it. Here’s what we confirmed and when.

Last verified: June 16, 2026. We checked LillyDirect, NovoCare, Ro, CMS, FDA statements, and ClinicalTrials.gov on this date.

We’re publishing this because we’d want a friend reading it to get the truth, not a sales pitch dressed as advice.

Frequently asked questions

Sources

• Amgen — MARITIME Phase 3 program. amgen.com
• ClinicalTrials.gov — MARITIME-1 (NCT06858839), MARITIME-2 (NCT06858878), MARITIME-CV (NCT07037433), MARITIME-HF (NCT07037459), MARITIME-OSA-1/-2 (NCT07225686, NCT07226765)
• Jastreboff A.M. et al., “Once-Monthly Maridebart Cafraglutide for Obesity — A Phase 2 Trial,” NEJM, 2025
• SURMOUNT-5 (tirzepatide 20.2% vs semaglutide 13.7%) — Eli Lilly / NEJM; American College of Cardiology
• Novo Nordisk / FDA — Wegovy HD (semaglutide 7.2 mg) approval, STEP UP 20.7% / 18.8% (March 2026)
• Novo Nordisk / FDA — Wegovy pill (oral semaglutide 25 mg) approval, OASIS 4 16.6% / 13.6% (Dec 2025)
• Eli Lilly / FDA — Foundayo (orforglipron) approval and pricing (April 2026); ATTAIN-1 (12.4% at 72 weeks)
• LillyDirect — Zepbound self-pay pricing ($299 / $399 / $449); NovoCare — Wegovy / Wegovy HD / pill pricing
• FDA — shortage resolutions (tirzepatide Oct/Dec 2024, semaglutide Feb 2025); compounding “essentially a copy” guidance; April 30, 2026 proposed 503B bulks exclusion; 30+ telehealth warning letters; consumer warnings on unapproved GLP-1 products
• CMS — Medicare GLP-1 Bridge ($50/month, July 1, 2026 – December 31, 2027; Foundayo, Wegovy injection/tablets, Zepbound KwikPen; vials/pens excluded)
• Ro — formulary, Ro Body membership, insurance concierge, GLP-1 Insurance Coverage Checker

Prices, availability, and regulatory status change often. We re-verify pricing and FDA status monthly and update the “Last verified” date with each check.